Bank of The Ozarks increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 24.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 8,723 shares of the company’s stock after buying an additional 1,740 shares during the period. Bank of The Ozarks’ holdings in Eli Lilly and were worth $734,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the stock. First Command Financial Services Inc. raised its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co bought a new stake in shares of Eli Lilly and during the first quarter worth approximately $135,000. Penserra Capital Management LLC raised its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in shares of Eli Lilly and during the first quarter worth approximately $179,000. Finally, Alpha Windward LLC increased its position in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the period. 75.61% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Company (NYSE:LLY) traded down 0.47% during trading on Friday, reaching $81.15. 2,446,392 shares of the company traded hands. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The company’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.72. The firm has a market capitalization of $85.61 billion, a price-to-earnings ratio of 35.11 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the business posted $0.86 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio is currently 90.04%.
TRADEMARK VIOLATION WARNING: This piece was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/08/13/eli-lilly-and-company-lly-position-boosted-by-bank-of-the-ozarks-updated-updated.html.
A number of research analysts recently weighed in on LLY shares. BMO Capital Markets set a $71.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Credit Suisse Group reissued an “outperform” rating and issued a $87.00 price objective on shares of Eli Lilly and in a research report on Wednesday, April 19th. Jefferies Group LLC restated a “buy” rating and set a $92.00 target price (down previously from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Finally, Berenberg Bank restated a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research note on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $88.27.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.